Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziresovir (AK0529) in High-Risk Adults with RSV Infection
NCT07658534Phase 3Recruiting
- Sponsor
- Ark Biosciences
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ziresovir in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Ark Biosciences. Primary endpoint: Time from first dose to resolution of lower respiratory tract disease (LRTD) symptoms. Started Mar 2026; status: recruiting.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07658534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07658534.